Showing 3531-3540 of 7509 results for "".
- Increased Cost Diminishes Sunscreen Use: Reporthttps://practicaldermatology.com/news/cost-influences-sunscreen-use-raising-skin-cancer-risk-study-shows/2474206/Patients use less sunscreen when it’s more expensive, according to a brief report in the Journal of the American Academy of Dermatology. Researchers from the University of California, Sa
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- ICONIC-LEAD: Oral Icotrokinra Clears Skin in 75% of Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/oral-icotrokinra-clears-skin-in-75-of-adolescents-with-plaque-psoriasis/2474078/Icotrokinra, an investigational oral IL-23 receptor antagonist, led to completely clear skin in 75% of adolescents with moderate-to-severe plaque psoriasis by week 24, according to results presented at the 2025 World Congress of Pediatric Dermatology.
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- Analysis: Proximity to Tanning Facilities Correlates with Increased Melanoma Incidence in New Englandhttps://practicaldermatology.com/news/analysis-proximity-to-tanning-facilities-correlates-with-increased-melanoma-incidence-in-new-england/2473824/Results from a new analysis suggest a correlation between proximity to tanning facilities and higher melanoma inc
- No Link Between PCSK9 Inhibitors and Vitiligo Risk: Studyhttps://practicaldermatology.com/news/analysis-no-link-between-pcsk9-inhibitors-and-vitiligo-risk/2471859/New research published in the Journal of Investigative Dermatology shows no evidence linking PCSK9 inhibitors to an increased risk of vitiligo. Researchers exploring whether inhibiting PCSK9
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- Biologics Linked to Lower Infection Risk in Older Psoriatic Patients: Studyhttps://practicaldermatology.com/news/biologics-linked-to-lower-infection-risk-in-older-psoriatic-patients-study/2471809/Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with lower rates of serious infection in older adults with psoriatic disease, according to a cohort study using Ontario health data. The study, publishe